Role of new diagnostic test i.e. Interferon Gamma Release Assay (IGRA)in diagnosis and prognosis of tuberculous meningitis patients
- Registration Number
- CTRI/2010/091/003048
- Lead Sponsor
- I
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 40
1.Fever, headache, meningismus, other signs and clinical presentations of meningitis of more than 2 weeks duration.
2.Typical cerebrospinal fluid (CSF) features including pleocytosis with more than 20 cells, lymphocytes greater than 60%, protein greater than 100mg% and glucose level less than 60% of the corresponding blood glucose level.
Presumptive diagnosis of TBM will be made based on the clinical criteria with typical CSF features and at least one of the following supporting criteria:
1.Radiographic findings based on chest X-ray that confirmed pulmonary TB (reticulonodular pattern in upper lobes with or without cavitatory lesions),
2. Hydrocephalous from brain computerized tomography (CT) scan,
3.Response to anti-tuberculous treatment after 4 weeks.
1.The patients who already received more than 30 days of antituberculous drugs and steroids.
2.The patient declined to give consent.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Death or severe disability assessed by modified Rankin scaleTimepoint:
- Secondary Outcome Measures
Name Time Method ILTimepoint: NI